NRx Logo
  • Our Company
  • Our Therapeutic Focus
    • Our Focus on the Brain
    • Bipolar Depression & Suicidality
    • Post-Traumatic Stress Disorder
  • Our Science
    • Our Clinical Approach
    • NRX-100/NRX-101
    • Mechanism of Action
    • NMDA & 5HT2A receptors
    • Publications & Literature
  • Pipeline
  • Investors / Media
  • Investor Relations
  • Presentation
  • Clinical Trials
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Analyst Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Analyst Coverage
  • IR Calendar
  • Email Alerts
Jul 13, 2022 7:15am EDT

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Jul 01, 2022 7:23am EDT

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

Jun 23, 2022 7:45am EDT

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Jun 22, 2022 6:33pm EDT

Class Action Suit Against NRx Pharmaceuticals Dismissed

Jun 10, 2022 10:47pm EDT

NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)

Jun 07, 2022 8:02pm EDT

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

May 26, 2022 12:03am EDT

NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

May 19, 2022 7:20am EDT

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference

May 16, 2022 7:12am EDT

NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

May 12, 2022 8:17am EDT

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 16
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin